Telix Gets Chinese Nmpa Approval To Begin Pivotal Phase Iii Study Of Tlx591-Cdx For Prostate Cancer Imaging
Telix Pharmaceuticals Limited, A Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic And Therapeutic Radiopharmaceuticals, Announces That The Chinese National Medical Products Administration (Nmpa) Center For Drug Evaluation (Cde) Has Approved An Investigational New Drug (Ind) Application To Commence A Pivotal Phase Iii Registration Study Of Tlx591-Cdx (Kit For The Preparation Of 68Ga-Psma-11), For The Imaging Of Prostate Cancer Using Positron Emission Tomography (Pet) That Will Bridge To The Marketing Authorisation Granted To Illuccix By The United States Food And Drug Administration (Fda).The Ind Application Was Submitted In Partnership With Grand Pharmaceutical Group Limited (Grand Pharma), Telix
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
